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operative day and was excluded from the analysis, although was included in the cumulative survival rate. The intervention group subsequently included 22 patients. No control group was used and the comparative effectiveness data were taken from published studies. No details were provided on the suitability of the initial study sample to the clinical study question.
Study design
This was a single-centre cohort study of a 20-week ganciclovir prophylaxis regimen, compared with published studies of shorter duration. The duration of follow-up for the latter, i.e. control groups, was: 25 months for the 3-week course; 8 months for the 5-week course and 23 months for the 12-week course. Clinicians assessed outcome and were not blinded.
Analysis of effectiveness
All patients (n=22), with the exception of one who died on post-operative day 1, were included in the analysis. In addition, the total sample (n=23) was used to calculate the cumulative overall survival rate.
The primary outcome was the number of patients who developed CMV infections, although the presence of CMV disease and CMV-attributed mortality were also recorded. Infection was defined as detection of CMV through the shell vial assay on the blood, sputum or BAL fluid samples. CMV disease was established when a symptomatic infection was accompanied by lung function decline, radiological infiltrates, or the presence of viral inclusions of histologic specimens obtained through biopsies, without the presence of any other identified pathogen to suggest a concomitant causal disease. Patients measured their own lung function status on a daily basis at home. Bronchoscopy procedures were performed at 0, 2, 7, 14 and 28 days, and at 3, 6, 9 and 12 months. CMV infection was evaluated twice a month in the first year following transplantation, and once a month thereafter. Adverse effects of ganciclovir were monitored using a 20% increase in serum creatinine and/or a polymorphonuclear count of less than 2 mL. The indications for lung transplantation varied in the patient sample. Patients (n=22) undergoing the 20-week prophylaxis with ganciclovir received standardised immunosuppressive therapies. In 15 patients, the CMV serotype (positive or negative) did not match the donors.
Effectiveness results
For the 20-week course the results were as follows:
reported number of CMV infections, 11; cumulative CMV infections at 1 year, 29%; reported number of patients with CMV disease, 1;
reported number of patients with CMV-attributed mortality, 0.
No confidence intervals were reported. Ten patients in the intervention group presented at least one complication that could be attributed to either ganciclovir use or to long-term catheter use.
Clinical conclusions
See 'Results of the Review' for a comparison of the results from this study with those from a review of the literature. The authors stated that their results showed lower long-term rates of CMV infections in patients treated with the 20-week ganciclovir regimen, than in those treated with shorter-term regimens. They concluded that there were additional benefits with extended ganciclovir prophylaxis during the period of maximal immunosuppression, which both decreased short-term rates of CMV infection and delayed their onset.
Modelling
The Kaplan and Meier product-limit method was used to calculate the cumulative overall survival rate and the incidence
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Outcomes assessed in the review
The outcomes assessed were the number of patients who developed CMV infections, the presence of CMV disease, and CMV-attributed mortality.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two primary studies were included.
Methods of combining primary studies
Not applicable; only one study provided the estimate for each duration of treatment.
Investigation of differences between primary studies
The primary studies were compared in terms of diagnostic criteria, immunosuppression protocol, and duration of followup.
Results of the review
The The cumulative CMV infections at 1 year were: 75% for the 3-week course, 31% for the 5-week course, and 58% for the 12-week course.
The reported number of patients with CMV disease were: 4 for the 3-week course, 29 for the 5-week course, and 0 for the 12-week course.
